MA33746B1 - Combinaison - Google Patents

Combinaison

Info

Publication number
MA33746B1
MA33746B1 MA34863A MA34863A MA33746B1 MA 33746 B1 MA33746 B1 MA 33746B1 MA 34863 A MA34863 A MA 34863A MA 34863 A MA34863 A MA 34863A MA 33746 B1 MA33746 B1 MA 33746B1
Authority
MA
Morocco
Prior art keywords
pharmaceutically acceptable
acceptable salt
raf
mek
inhibitor
Prior art date
Application number
MA34863A
Other languages
Arabic (ar)
English (en)
Inventor
Melissa Dumble
Rakesh Kumar
Sylvie Laquerre
Peter Lebowitz
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43876568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33746(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA33746B1 publication Critical patent/MA33746B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'INVENTION CONCERNE UNE NOUVELLE COMBINAISON COMPRENANT L'INHIBITEUR DE MEK N-{3-[3-CYCLOPROPYL-5- (2-FLUORO-4-IODO-PHÉNYLAMINO)6,8-DIMÉTHYL; -2,4,7-TRIOXO-3,4,6,7-TÉTRAHYDRO-2H-PYRIDO [4,3-D]PYRIMIDIN-1-YL]PHÉNYL}ACÉTAMIDE OU UN SEL OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI AVEC UN INHIBITEUR DE B-RAF, EN PARTICULIER LE N-{3- [5-(2-AMINO-4-PYRIMIDINYL)-2-(1,1-DIMÉTHYLÉTHYL)-1, 3-THIAZOL-4-YL]-2-FLUOROPHÉNYL}-2,6-DIFLUOROBENZÈNESULFONAMIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, DES COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT ET DES PROCÉDÉS D'UTILISATION DE TELLES COMBINAISONS ET COMPOSITIONS DANS LE TRAITEMENT D'ÉTATS PATHOLOGIQUES DANS LESQUELS L'INHIBITION DE MEK ET/OU B-RAF EST BÉNÉFIQUE, PAR EXEMPLE LE CANCER.
MA34863A 2009-10-16 2012-05-11 Combinaison MA33746B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25221309P 2009-10-16 2009-10-16
PCT/US2010/052808 WO2011047238A1 (fr) 2009-10-16 2010-10-15 Combinaison

Publications (1)

Publication Number Publication Date
MA33746B1 true MA33746B1 (fr) 2012-11-01

Family

ID=43876568

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34863A MA33746B1 (fr) 2009-10-16 2012-05-11 Combinaison

Country Status (35)

Country Link
US (3) US8703781B2 (fr)
EP (5) EP3560498B1 (fr)
JP (1) JP5718929B2 (fr)
KR (1) KR101729116B1 (fr)
CN (1) CN102655753B (fr)
AU (1) AU2010306653B2 (fr)
BR (1) BR112012008854B8 (fr)
CA (1) CA2775803C (fr)
CL (1) CL2012000964A1 (fr)
CO (1) CO6531498A2 (fr)
CR (1) CR20120155A (fr)
CY (1) CY1122013T1 (fr)
DK (4) DK3560498T3 (fr)
DO (1) DOP2012000091A (fr)
EA (1) EA020589B1 (fr)
ES (3) ES2986037T3 (fr)
FI (2) FI4397376T3 (fr)
HR (2) HRP20221304T1 (fr)
HU (3) HUE067723T2 (fr)
IL (1) IL219073A (fr)
LT (4) LT4159217T (fr)
MA (1) MA33746B1 (fr)
ME (1) ME03497B (fr)
MX (1) MX2012004413A (fr)
MY (1) MY174759A (fr)
NZ (1) NZ598913A (fr)
PE (1) PE20121093A1 (fr)
PH (1) PH12012500742A1 (fr)
PL (3) PL4159217T3 (fr)
PT (4) PT4159217T (fr)
RS (3) RS65800B1 (fr)
SI (2) SI4159217T1 (fr)
UA (1) UA105064C2 (fr)
WO (1) WO2011047238A1 (fr)
ZA (1) ZA201202612B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
UA105005C2 (uk) 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Сполуки для лікування раку
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN103038364A (zh) * 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
US20130217710A1 (en) * 2010-11-05 2013-08-22 Glaxosmithkline Intellectual Property (No.2) Limited Methods for treating cancer
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
CN104066445A (zh) * 2011-12-22 2014-09-24 葛兰素史克有限责任公司 用mage-a3免疫治疗剂与braf抑制剂和/或mek抑制剂治疗癌症的方法
CN104428001A (zh) * 2012-03-30 2015-03-18 武田药品工业有限公司 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
AU2013313050A1 (en) * 2012-09-04 2015-03-26 Novartis Ag Method of adjuvant cancer treatment
EP2911673A4 (fr) * 2012-10-25 2016-05-18 Novartis Ag Combinaison
US20150328320A1 (en) * 2012-11-30 2015-11-19 Glaxosmithkline Llc Novel Pharmaceutical Composition
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
EP2964028A4 (fr) * 2013-03-05 2017-06-07 University of Tennessee Research Foundation Composés pour le traitement du cancer
JP6720075B2 (ja) * 2013-05-31 2020-07-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌のための併用療法
HK1216231A1 (zh) * 2013-06-03 2016-10-28 Novartis Ag Anti-pd-l1抗体及mek抑制剂及/或braf抑制剂的混合物
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
WO2015059677A1 (fr) * 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Méthodes de traitement du cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
BR112016011222A2 (pt) * 2013-12-12 2017-09-19 Novartis Ag Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer
EP3378952B1 (fr) 2013-12-28 2020-02-05 Guardant Health, Inc. Procédés et systèmes de détection de variants génétiques
WO2015105822A1 (fr) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Procédé de traitement du cancer
RU2733393C9 (ru) 2014-05-06 2021-09-09 Джи Ти Икс, ИНК. Соединения для лечения рака
KR101629184B1 (ko) 2014-12-10 2016-06-13 현대오트론 주식회사 Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법
WO2017033113A1 (fr) 2015-08-21 2017-03-02 Acerta Pharma B.V. Associations thérapeutiques d'un inhibiteur de mek et d'un inhibiteur de btk
WO2018085674A1 (fr) * 2016-11-03 2018-05-11 The Regents Of The University Of Michigan Inhibiteurs doubles à petite molécule d'egfr/pi3k et leurs utilisations
WO2020079581A1 (fr) 2018-10-16 2020-04-23 Novartis Ag Charge mutationnelle tumorale seule ou en combinaison avec des marqueurs immunitaires comme biomarqueurs pour prédire une réponse à une thérapie ciblée
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
TW202118488A (zh) * 2019-07-26 2021-05-16 大陸商蘇州亞盛藥業有限公司 Mdm2抑制劑的藥物組合物及其在預防和/或治療疾病中的用途
AU2020326612B2 (en) 2019-08-02 2025-10-23 Onehealthcompany, Inc. Treatment of canine cancers
CA3159348A1 (fr) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methodes pour le traitement de cancers qui ont acquis une resistance aux inhibiteurs de kinase
JP7769388B2 (ja) 2019-12-12 2025-11-13 ティン セラピューティクス，インコーポレイテッド 聴覚損失の予防及び治療のための組成物及び方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
US20230084515A1 (en) * 2020-02-19 2023-03-16 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
EP4308935A1 (fr) 2021-03-18 2024-01-24 Novartis AG Biomarqueurs pour le cancer et leurs méthodes d'utilisation
EP4426304A4 (fr) * 2021-11-02 2025-11-26 Verastem Inc Méthodes de traitement de croissance cellulaire anormale
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025073765A1 (fr) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Méthodes de pronostic et de traitement de patients souffrant de mélanome
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
HK1050190A1 (zh) 1999-11-22 2003-06-13 Smithkline Beecham Plc 咪唑衍生物和它们做为raf激酶抑制剂的用途
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP4163738B2 (ja) * 2004-06-11 2008-10-08 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
WO2008120004A1 (fr) * 2007-04-02 2008-10-09 Astrazeneca Ab Combinaison d'un inhibiteur de mek et d'un inhibiteur de b-raf pour le traitement du cancer
CA2924436A1 (fr) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinaisons pharmaceutiques de n-3(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide comme inhibiteurs de mek et methodes d'utilisation
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
PT3560498T (pt) 2022-11-03
PL2488033T3 (pl) 2019-12-31
SI4159217T1 (sl) 2024-09-30
IL219073A0 (en) 2012-06-28
WO2011047238A1 (fr) 2011-04-21
EP4159217A1 (fr) 2023-04-05
HRP20191617T1 (hr) 2019-12-13
AU2010306653A1 (en) 2012-05-10
DK4397376T3 (da) 2026-02-23
EP3560498A1 (fr) 2019-10-30
ME03497B (fr) 2020-04-20
NZ598913A (en) 2013-11-29
JP2013508294A (ja) 2013-03-07
PT2488033T (pt) 2019-09-10
CR20120155A (es) 2012-07-05
EP4159217B1 (fr) 2024-05-22
MY174759A (en) 2020-05-13
EP4397376B1 (fr) 2025-11-26
ES2745479T3 (es) 2020-03-02
ES2930157T3 (es) 2022-12-07
ZA201202612B (en) 2013-09-25
US20150111904A1 (en) 2015-04-23
LT3560498T (lt) 2022-11-25
EA201290149A1 (ru) 2012-11-30
EP4706770A2 (fr) 2026-03-11
ES2986037T3 (es) 2024-11-08
US8703781B2 (en) 2014-04-22
DK3560498T3 (da) 2022-11-14
CA2775803A1 (fr) 2011-04-21
AU2010306653B2 (en) 2013-10-24
LT4159217T (lt) 2024-08-26
FI4397376T3 (fi) 2026-02-24
PT4159217T (pt) 2024-08-12
KR101729116B1 (ko) 2017-05-02
US20120196879A1 (en) 2012-08-02
US8952018B2 (en) 2015-02-10
BR112012008854A2 (pt) 2015-09-22
RS59181B1 (sr) 2019-10-31
HRP20221304T1 (hr) 2022-12-23
EP4397376A2 (fr) 2024-07-10
EP2488033B1 (fr) 2019-06-12
PL3560498T3 (pl) 2022-12-12
CO6531498A2 (es) 2012-09-28
KR20120104547A (ko) 2012-09-21
EP2488033A4 (fr) 2014-04-30
FI4159217T3 (fi) 2024-08-15
DK2488033T3 (da) 2019-09-02
RS65800B1 (sr) 2024-08-30
PL4159217T3 (pl) 2024-09-30
PT4397376T (pt) 2026-02-24
EA020589B1 (ru) 2014-12-30
EP2488033A1 (fr) 2012-08-22
DOP2012000091A (es) 2013-09-15
BR112012008854B8 (pt) 2021-05-25
US20140187566A1 (en) 2014-07-03
RS63702B1 (sr) 2022-11-30
UA105064C2 (uk) 2014-04-10
CN102655753A (zh) 2012-09-05
IL219073A (en) 2016-05-31
EP4397376A3 (fr) 2024-10-30
EP3560498B1 (fr) 2022-08-17
LT4397376T (lt) 2026-03-10
DK4159217T3 (da) 2024-08-12
CN102655753B (zh) 2015-11-25
PE20121093A1 (es) 2012-09-04
HUE067723T2 (hu) 2024-11-28
BR112012008854B1 (pt) 2020-12-29
JP5718929B2 (ja) 2015-05-13
LT2488033T (lt) 2019-09-10
HUE046139T2 (hu) 2020-02-28
CA2775803C (fr) 2017-11-21
PH12012500742A1 (en) 2015-12-11
SI2488033T1 (sl) 2019-10-30
CL2012000964A1 (es) 2012-08-31
HUE060206T2 (hu) 2023-02-28
KR101729116B9 (ko) 2026-02-05
CY1122013T1 (el) 2020-10-14
MX2012004413A (es) 2012-05-08

Similar Documents

Publication Publication Date Title
MA33746B1 (fr) Combinaison
MA38643A1 (fr) Combinaisons d'un anticorps anti-pd-l1 et d'un inhibiteur de mek et/ou d'un inhibiteur de braf
HRP20160447T1 (hr) Spojevi benzensulfonamid-tiazola i benzensulfonamid-oksazola
MA31205B1 (fr) Combinaisons d'agents therapeutiques pour le traitement du cancer
MA52424B1 (fr) Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide
MA37711A1 (fr) Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
WO2014066606A3 (fr) Combinaison
MA33491B1 (fr) Composition pharmaceutique pour un inhibiteur de protease virale de l'hépatite c
JP2013535487A5 (fr)
MA30672B1 (fr) Utilisation de derives de l'azabicyclo hexane
MX2009002239A (es) Derivados de 5-(2-furil)-1,3-tiazol util como inhibidores de fosfatidilinositol 3-cinasa.
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
BR112016011222A2 (pt) Combinações de trametinib, panitumumab e dabrafenib para o tratamento de câncer
MA35716B1 (fr) Formulations pharmaceutiques
MA44935A1 (fr) Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires
JP2016512507A5 (fr)
RU2009142557A (ru) Применение фунгицидов для обработки микозов у рыб
MA53427B1 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
MA35636B1 (fr) Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide
MA53561B1 (fr) Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k)
CN109689657A (zh) 氘代3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
RU2015120692A (ru) Производное 6-оксо-1,6-дигидро-пиридизина для применения в лечении гепатоцеллюлярной карциномы (гцк)
JP2009501744A5 (fr)
MA39032A1 (fr) Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë
TW200616625A (en) Agent for prophylaxis or treatment of metabolic syndrome